{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T21:46:37Z","timestamp":1775771197790,"version":"3.50.1"},"reference-count":18,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"3","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2023,3,28]]},"DOI":"10.1167\/tvst.12.3.28","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T14:31:13Z","timestamp":1680013873000},"page":"28","source":"Crossref","is-referenced-by-count":5,"title":["Sustained Ocular Delivery of Bevacizumab Using Densomeres in Rabbits: Effects on Molecular Integrity and Bioactivity"],"prefix":"10.1167","volume":"12","author":[{"given":"Jan S.","family":"Peterson","sequence":"first","affiliation":[{"name":"Sustained Nano Systems, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WeiLiam","family":"Chen","sequence":"additional","affiliation":[{"name":"Sustained Nano Systems, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry M.","family":"Libin","sequence":"additional","affiliation":[{"name":"Sustained Nano Systems, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[{"name":"Sustained Nano Systems, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter K.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Sustained Nano Systems, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Liebmann","sequence":"additional","affiliation":[{"name":"Sustained Nano Systems, Long Island High Technology Incubator, Stony Brook, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"627674","DOI":"10.1155\/2015\/627674","article-title":"Anti-VEGF therapy and the retina: An update","volume":"2015","author":"Tah","year":"2015","journal-title":"J Ophthalmol"},{"issue":"10326","key":"bib2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"10326","key":"bib3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"bib4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","article-title":"PLGA-based biodegradable microspheres in drug delivery: Recent advances in research and application","volume":"28","author":"Su","year":"2021","journal-title":"Drug Deliv"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"787644","DOI":"10.3389\/fmed.2021.787644","article-title":"Considerations for polymers used in ocular drug delivery","volume":"8","author":"Allyn","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"bib6","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"bib7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/ICO.0b013e3182801645","article-title":"Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model","volume":"32","author":"Ko","year":"2013","journal-title":"Cornea"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000322061","article-title":"Prevention of corneal neovascularization: Comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats","volume":"46","author":"Hashemian","year":"2011","journal-title":"Ophthalmic Res"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/jcm10050981","article-title":"Inflammatory complications of intravitreal anti-VEGF injections","volume":"10","author":"Cox","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"bib10","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (Lond)"},{"issue":"2","key":"bib12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: A newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajo.2022.06.005","article-title":"Anti-vascular endothelial growth factor treatment discontinuation and interval in neovascular age-related macular degeneration in the United States","volume":"242","author":"Bakri","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"bib15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am J Pathol"},{"issue":"11","key":"bib16","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"issue":"12","key":"bib17","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1167\/iovs.09-4571","article-title":"The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency","volume":"51","author":"Lin","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"bib18","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2785480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T14:31:16Z","timestamp":1680013876000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2785480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.12.3.28","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}